Merck KGaA Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib. AmoyDx Strikes CDx Development Deal for Merck KGaA Cancer Drug AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan. Metabolon, Merck KGaA Form Metabolomics Alliance Metabolon's Precision Metabolomics platform identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways. Japanese Regulators Approve Merck KGaA MET Inhibitor With ArcherDx CDx The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 14 skipping alterations. Personalis, Merck KGaA to Study Cancer Biomarkers Using Immunogenomics Platform The partners plan to employ Personalis' ImmunoID NeXT platform to investigate biomarkers of response and mechanisms of resistance to cancer therapies. Sep 23, 2019 Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium Oct 3, 2018 Merck KGaA, ArcherDx Partner to Develop CDx for Downstream Therapeutic Sep 10, 2018 Definiens, Merck KGaA Partner for Biomarker Discovery Jun 20, 2018 Merck KGaA Advancing Tepotinib in MET-Altered Cancer Subpopulations Premium Jan 10, 2018 ThermaGenix, MilliporeSigma Ink PCR Reagents Distribution Deal Dec 27, 2017 HTG Expands Collaboration With Merck KGaA Nov 27, 2017 Biocartis Gets CE Marking for Two Colorectal Cancer Liquid Biopsy Tests Sep 26, 2017 FDA Gives Guardant Health IDE Approval for Clinical Trial of Merck KGaA Cancer Drug Jun 15, 2017 Human Longevity, Merck KGaA Form Cancer Biomarker Partnership Jun 13, 2017 MilliporeSigma's Proxy-CRISPR Tech Aims to Increase Usability of Native CRISPR Proteins Premium May 30, 2017 Lonza's New Investments in Exosome Technologies Reflect Growing Industry Interest Premium Apr 11, 2017 MilliporeSigma Developing New Instrument for Single-Molecule Biomarker Detection Premium Jan 6, 2017 Guardant Health, Pharma Firms to Develop 500-Gene Liquid Biopsy Panel Dec 1, 2016 Roche, Merck KGaA Expand PCR Distribution Agreement Nov 30, 2016 Evotec Inks Deal to Offer Merck KGaA Gene Editing, Silencing Technologies Oct 12, 2016 HTG, Merck KGaA Ink CDx Development Deal for Lymphoma Drug Jul 28, 2016 Merck KGaA, AmoyDx Partner on Colorectal Cancer Test for Chinese Market Apr 15, 2016 Expansion of Liquid Biopsy Test Sites Planned by Merck KGaA, Sysmex Premium Apr 7, 2016 Merck KGaA, Sysmex Inostics Garner CE Mark for Liquid Biopsy CRC Test Mar 8, 2016 Merck KGaA's 2015 Sales Jump on Life Sciences Contribution, Sigma-Aldrich Acquisition Load More Breaking News Alzheimer's Disease Phosphoproteomics Study Uncovers Signaling Abnormalities Genetic Analysis of H. Pylori Indicates Americas Colonized in One Main Migration Event BillionToOne Raises $55M in Series B Financing GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana Top Five Articles on GenomeWeb Last Week: Illumina, Liquid Biopsy, Thermo Fisher Scientific, and More Becton Dickinson Sues Beckman Coulter Over Cell Analysis, Sorting IP The Scan Another Resignation According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug. Novavax Finds Its Vaccine Effective Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19. Can't Be Used The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports. PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.